Elanco Files Routine 8-K; Confirms Non-Emerging Growth Status

TL;DR

**Elanco's 8-K is a standard administrative filing with no new material news.**

AI Summary

Elanco Animal Health Incorporated filed an 8-K on January 2, 2024, primarily to disclose general corporate information and confirm its status as a non-emerging growth company. This filing, under SEC File Number 001-38661, indicates standard compliance and does not reveal new financial or operational events. For investors, this means there are no immediate new developments, positive or negative, that would significantly impact their investment decision based solely on this filing.

Why It Matters

This filing is largely administrative, confirming Elanco's status and providing contact information, which means no new material information affecting the stock price is disclosed.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not introduce any new financial or operational risks.

Analyst Insight

Investors should note this is a standard administrative filing and does not contain new material information that would warrant immediate action. Continue to monitor for future filings that may contain financial results or strategic announcements.

Key Players & Entities

• Elanco Animal Health Incorporated (company) — the registrant filing the 8-K
• January 2, 2024 (date) — date of earliest event reported and filing date
• 001-38661 (dollar_amount) — Commission File Number for Elanco
• ELAN (company) — trading symbol for Elanco's common stock
• New York Stock Exchange (company) — exchange where Elanco's common stock is registered

FAQ

From the Filing

0001104659-24-000140.txt : 20240102 0001104659-24-000140.hdr.sgml : 20240102 20240102090742 ACCESSION NUMBER: 0001104659-24-000140 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240102 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24500512 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2334009d1_8k.htm FORM 8-K false 0001739104 0001739104 2024-01-02 2024-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION W ashington , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) : January 2, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 7.01 Regulation FD Disclosure.   A copy of the press release issued by Elanco Animal Health Incorporated (the “Company”) announcing certain planned Board of Director and Committee leadership changes and proposed voting standard change is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01, including the information contained in the accompanying Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be i